Navigation Links
Carefully Monitored Treatment Can Help Those Who Suffer from Depression

More than two-thirds of people who suffer from major depression can become symptom-free if they are willing to work with their doctors //and try various treatments to determine which work best for them, which may involve taking different antidepressants or adding cognitive therapy to the mix.

The largest study on treatments for depression, led by UT Southwestern Medical Center, found that 67 percent of patients achieved a full remission of symptoms by the end of one to four treatment steps. An overview of the $35 million, six-year study – designated STAR*D (Sequenced Treatment Alternatives to Relieve Depression) and funded by the National Institute of Mental Health (NIMH) – appears in the November issue of the American Journal of Psychiatry.

Results showed that the chances of reaching remission were higher after the first and second treatment steps (37 percent and 31 percent respectively), than after the third and fourth steps (14 percent and 13 percent). For those who did improve or remit in fewer treatment steps, lower relapse rates were found during a 12-month follow-up than for those who required more steps to reach remission or improvement.

“There’s good news and not-so-good news,” said Dr. A. John Rush, vice chairman of clinical sciences and professor of psychiatry at UT Southwestern. “The good news is that two-thirds of people can be relieved of their depression if they can hang in there for up to four treatment steps. That’s pretty significant for a tough illness.

“The not-so-good news is that when more steps are needed to get to remission or meaningful improvement, the higher the risk is for having a return of the depressive episode – or a relapse,” said Dr. Rush, the study’s principal investigator.

STAR*D is the first benchmark study to implement specific step-by-step medication treatment guidelines based on patients’ symptoms and medication side effects. This gives clinicians a “measurement-based care” approach to delivering high-quality treatment for depression.

An important feature of the landmark clinical trial is that the 3,671 patients included were treated in “real-world” settings – 41 primary-care and psychiatric clinics around the country – rather than being nonpatient volunteers, as often is the case in such studies. In addition to suffering from major depression, most had other coexisting general medical and psychiatric conditions.

All participants initially received the same antidepressant medication. Those who didn’t experience remission or couldn’t tolerate the medication were strongly encouraged to proceed to the next step, where they were randomized to various groups receiving subsequent treatments including cognitive therapy alone or in combination with medication, as well as several different antidepressants used alone or in combination. Once patients achieved remission or made substantial improvement, they were followed closely for another 12 months.

“This report provides a summary of all the steps and a comprehensive view of outcomes from the largest depression trial ever conducted,” said Dr. Madhukar Trivedi, co-author of the study and professor of psychiatry at UT Southwestern. “It offers clear evidence of what happens step-by-step and gives us a good idea of what outcomes will be the following year, if patients continue the same treatment.”

Each year, about 21 million American adults – or 9.5 percent of the population – struggle with depression, often a recurring or chronic disorder. Depression frequently returns two or more times, with some episodes lasting two years or more.

“Depression is a disabling medical condition just like any other medical condition such as diabetes or congestive heart failure,” Dr. Rush said. “The take-home message for patients is to hang in there and stay in treatment, even if several steps and various medications must be tried. Be patient and willin g to tell your doctor if a medication isn’t working, if the dosage is bothering you or if you’re having side effects. Collaborate with your physician to find the right medication and dosage for you, and stay on it long enough to give it a chance to work.”

For clinicians, the study emphasizes the need for careful and regular monitoring and evaluation of patients, as well as highlights the critical value of remission as the end objective, Dr. Rush said.

“Remission is the thing you really, really want to try and achieve. And, follow-up is critical,” he said. “The more steps it takes to get better or to remission, the more carefully a patient needs to be followed, because the more likely that individual is to have a relapse.”

While more research is needed, STAR*D offers “clues,” Dr. Rush said, into the types of patients who require longer treatment for depression. These include people who suffer from other chronic medical conditions and/or additional psychiatric disorders, and individuals who have experienced longer and more disabling periods of depression before seeking treatment.

As for the one-third of individuals who didn’t reach remission, possible explanations include:

· There may be some depressions for which medications don’t work.

· Individual biological and genetic differences, as well as life circumstances and other medical conditions, may render some medication treatments ineffective.

· People suffering from long bouts of depression might have been helped earlier in the course of the disease, but may not achieve remission after lengthy chronic depression.

“This study emphasizes the importance of long-term management of this disease,” Dr. Rush said. “The short-term matters, but the long-term matterseven more.”

Source-Newswise
SRM
'"/>




Related medicine news :

1. Epilepsy Needs To Be Managed Carefully
2. Malaria-curing Herb Must Be Carefully Farmed - WHO
3. Testosterone Replacement Therapy Safe If Monitored Appropriately
4. Drug Prices in India to be Monitored - NPPA to Tie up with ORG
5. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
6. Children Monitored For Obesity
7. Advances in Treatment of Cataracts
8. Recommendations for Treatment of Blood Pressue
9. Treatment for Menieres disease
10. Treatment for pre-menstrual syndrome is ineffective
11. Better Treatment for obesity
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology: